相似文献
1
Privileged scaffolds for library design and drug discovery.
Curr Opin Chem Biol. 2010 Jun;14(3):347-61. doi: 10.1016/j.cbpa.2010.02.018. Epub 2010 Mar 18.
2
Current strategies for diversity-oriented synthesis.
Curr Opin Chem Biol. 2010 Jun;14(3):362-70. doi: 10.1016/j.cbpa.2010.03.018. Epub 2010 Apr 19.
3
Privileged structures: efficient chemical "navigators" toward unexplored biologically relevant chemical spaces.
J Am Chem Soc. 2014 Oct 22;136(42):14629-38. doi: 10.1021/ja508343a. Epub 2014 Oct 13.
4
Revisiting Pyrimidine-Embedded Molecular Frameworks to Probe the Unexplored Chemical Space for Protein-Protein Interactions.
Acc Chem Res. 2024 Nov 19;57(22):3254-3265. doi: 10.1021/acs.accounts.4c00452. Epub 2024 Oct 31.
5
BioCores: identification of a drug/natural product-based privileged structural motif for small-molecule lead discovery.
Mol Divers. 2010 Feb;14(1):193-200. doi: 10.1007/s11030-009-9157-5. Epub 2009 May 26.
6
Biologically active metabolites in drug discovery.
Bioorg Med Chem Lett. 2021 Sep 15;48:128255. doi: 10.1016/j.bmcl.2021.128255. Epub 2021 Jul 7.
7
Fragment library design, synthesis and expansion: nurturing a synthesis and training platform.
Drug Discov Today. 2017 Jan;22(1):43-56. doi: 10.1016/j.drudis.2016.10.005. Epub 2016 Oct 26.
8
The emergence of the C-H functionalization strategy in medicinal chemistry and drug discovery.
Chem Commun (Camb). 2021 Oct 19;57(83):10842-10866. doi: 10.1039/d1cc04083a.
9
Privileged structures: applications in drug discovery.
Comb Chem High Throughput Screen. 2004 Aug;7(5):473-94. doi: 10.2174/1386207043328544.
10
Ternary resin-bound Dynamic Combinatorial Chemistry.
Chem Commun (Camb). 2012 Feb 18;48(15):2131-3. doi: 10.1039/c2cc17192a. Epub 2012 Jan 13.
引用本文的文献
1
Going beyond SMILES enumeration for data augmentation in generative drug discovery.
Digit Discov. 2025 Aug 14. doi: 10.1039/d5dd00028a.
2
Cu/ZnO@GO promoted green synthesis of novel dipyridopyrimidines: evaluation of biological activity and theoretical study of the mechanism using a DFT method.
RSC Adv. 2025 Aug 26;15(36):29424-29438. doi: 10.1039/d5ra04054j. eCollection 2025 Aug 18.
3
Harnessing Phytonanotechnology to Tackle Neglected Parasitic Diseases: Focus on Chagas Disease and Malaria.
Pharmaceutics. 2025 Aug 12;17(8):1043. doi: 10.3390/pharmaceutics17081043.
4
The Role of Trifluoromethyl and Trifluoromethoxy Groups in Medicinal Chemistry: Implications for Drug Design.
Molecules. 2025 Jul 18;30(14):3009. doi: 10.3390/molecules30143009.
5
Synthesis of Substituted 1,4-Benzodiazepines by Palladium-Catalyzed Cyclization of -Tosyl-Disubstituted 2-Aminobenzylamines with Propargylic Carbonates.
Molecules. 2025 Jul 17;30(14):3004. doi: 10.3390/molecules30143004.
6
Untargeted Diversity-Oriented Synthesis for the Discovery of New Antitumor Agents: An Integrated Approach of Inverse Virtual Screening, Bioinformatics, and Omics for Target Deconvolution.
J Med Chem. 2025 Aug 14;68(15):16483-16517. doi: 10.1021/acs.jmedchem.5c01344. Epub 2025 Jul 24.
7
SAR-Guided Development of Small-Molecule SERCA2a Activators: Discovery of Potent Indoline, Benzofuran, and Benzodioxole Analogs for Cardiovascular Applications.
J Med Chem. 2025 Aug 14;68(15):16306-16330. doi: 10.1021/acs.jmedchem.5c01192. Epub 2025 Jul 24.
8
Unravelling the target landscape of tranylcypromines for new drug discovery.
Acta Pharm Sin B. 2025 Jun;15(6):2985-3007. doi: 10.1016/j.apsb.2025.04.012. Epub 2025 Apr 14.
9
Advances in Copper and Nickel C─N and C─O Cross-Couplings of (Hetero)Aryl Chlorides Enabled by Ancillary Ligand Development.
Chemistry. 2025 Jul 22;31(41):e202501858. doi: 10.1002/chem.202501858. Epub 2025 Jul 4.
10
Chemoenzymatic Route toward a De Novo Enantioselective Total Synthesis of (S)-Baclofen Based on Metal-Catalyzed Hydroformylation and Enzymatic Transamination.
Chembiochem. 2025 Aug 22;26(15):e202500108. doi: 10.1002/cbic.202500108. Epub 2025 Jul 4.
本文引用的文献
1
Systematic analysis of public domain compound potency data identifies selective molecular scaffolds across druggable target families.
J Med Chem. 2010 Jan 28;53(2):752-8. doi: 10.1021/jm9014229.
2
Et2SBrSbCl5Br: an effective reagent for direct bromonium-induced polyene cyclizations.
Angew Chem Int Ed Engl. 2009;48(42):7899-903. doi: 10.1002/anie.200903834.
3
Design, synthesis and cruzain docking of 3-(4-substituted-aryl)-1,2,4-oxadiazole-N-acylhydrazones as anti-Trypanosoma cruzi agents.
Bioorg Med Chem. 2009 Sep 15;17(18):6682-91. doi: 10.1016/j.bmc.2009.07.068. Epub 2009 Aug 6.
4
2-Arylbenzothiazole as a privileged scaffold in drug discovery.
Curr Med Chem. 2009;16(19):2430-40. doi: 10.2174/092986709788682137.
5
From nature to drug discovery: the indole scaffold as a 'privileged structure'.
Mini Rev Med Chem. 2009 Jun;9(7):782-93. doi: 10.2174/138955709788452649.
6
Rhodanine as a privileged scaffold in drug discovery.
Curr Med Chem. 2009;16(13):1596-629. doi: 10.2174/092986709788186200.
7
Combinatorial library synthesis and biological evaluation of pyrazolo[4,3-e][1,4]diazepine as a potential privileged structure.
ChemMedChem. 2009 May;4(5):733-7. doi: 10.1002/cmdc.200800453.
8
Discovery of indoline-based, natural-product-like compounds as probes of focal adhesion kinase signaling pathways.
J Comb Chem. 2009 Mar 9;11(2):303-9. doi: 10.1021/cc8001525.
9
Natural products as an inspiration in the diversity-oriented synthesis of bioactive compound libraries.
Nat Prod Rep. 2008 Aug;25(4):719-37. doi: 10.1039/b706296f. Epub 2008 Apr 14.
10
Chemical proteomics-based drug design: target and antitarget fishing with a catechol-rhodanine privileged scaffold for NAD(P)(H) binding proteins.
J Med Chem. 2008 Aug 14;51(15):4571-80. doi: 10.1021/jm8002284. Epub 2008 Jul 11.
Zotero 插件